Vandetanib is a quinazoline that is 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline bearing additional methoxy and 4-bromo-2-fluorophenylamino substituents at positions 6 and 4 respectively. Used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a member of piperidines, a secondary amine, an aromatic ether, an organobromine compound, an organofluorine compound and a member of quinazolines.
